Showing 651 results
- Media Release /-- Approval based on efficacy and safety demonstrated in long-term study comparing 13.3 mg/24 h to 9.5 mg/24 h in declining mild to moderate Alzheimer's patients-- New higher dose of Exelon Patch…
- Media Release /
- Media Release /Novartis Pharmaceuticals Corporation (NPC) is aware of the recent Democratic Steering and Policy Committee session in the U.S. House of Representatives to discuss the Paycheck Fairness Act and…
- Media Release /
- Media Release /• Data from FREEDOMS study show Gilenya reduced relapses in patients who discontinued another MS therapy due to side effects or inadequate efficacy• Analyses of five clinical studies show Gilenya,…
- Media Release /
- Media Release /- "Together in MS" partners professional cycling team members with people living with MS for Bike MS rides on tandem bicycles across the country- Phil Keoghan, MS advocate and TV host, rides tandem…
- Media Release /
- Media Release /• In the trial, patients on Exelon Patch 13.3 mg/24 h showed less functional decline vs. 9.5 mg/24 h patch in mild to moderate Alzheimer’s disease• Numerical trend toward cognitive efficacy was seen…
- Media Release /
Pagination
- ‹ Previous page
- 1
- …
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- …
- 66
- › Next page